Newscast – Page 94 – media

Tiny ‘hearing’ device is 100,000 times thinner than your eardrum

The super small vibrating sensor can detect signals at the highest reported dynamic range of frequencies, up to ~110dB, at radio frequencies (RF) up to over 120MHz.
- Source: Engadget
- 1,218
- April 3, 2018
medical device Researches wearables
Parkinson’s gene initiates disease outside of the brain

Until very recently, Parkinson's had been thought a disease that starts in the brain, destroying motion centers and resulting in the tremors and loss of movement. New research published this week in the journal Brain, shows the most common Parkinson's gene mutation may change how immune cells react to generic infections like colds, which in turn trigger the inflammatory reaction in the brain that causes Parkinson's. The research offers a new understanding of Parkinson's disease.
- Source: sciencedaily
- 569
- April 2, 2018
immune cells Parkinson’s disease Researches
Calorie restriction trial in humans suggests benefits for age-related disease

One of the first studies to explore the effects of calorie restriction on humans showed that cutting caloric intake by 15% for 2 years slowed aging and metabolism and protected against age-related disease. The study, which will appear March 22 in the journal Cell Metabolism, found that calorie restriction decreased systemic oxidative stress, which has been tied to age-related neurological conditions such as Alzheimer's and Parkinson's diseases, as well as cancer, diabetes, and others.
- Source: sciencedaily
- 587
- April 2, 2018
aging calorie restriction metabolism Researches
Nine digital health mergers and acquisitions from the first quarter of 2018

The first quarter of 2018 was light on mergers and acquisitions compared to previous quarters, but those that did crop up were significant, including major companies like Fitbit, Allscripts, Roche, and Johnson & Johnson.
- Source: MobiHealthNews
- 509
- April 2, 2018
digital health Market Views merger-and-acquisition
Siren launches smart sock for diabetes patients, announces $3.4M in funding

The company, which was founded in 2015, also announced that it has raised $3.4 million in seed funding, from DCM, Khosla Ventures, and Founders Fund.
- Source: Mobile Health News
- 645
- April 2, 2018
Company Insights diabetes digital health mHealth
Third Rock debuts immunometabolism startup Rheos with $60M launch round

Global pharmaceutical company Mylan N.V. (MYL) today announced that it will introduce in the U.S. a third cost-saving HIV combination. The U.S. Food and Drug Administration (FDA) approved Symfi™ (efavirenz, lamivudine and tenofovir disoproxil fumarate) 600 mg/300 mg/300 mg tablets, a once-daily, single-tablet regimen (STR), indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 40 kg.
- Source: pharmacompass
- 646
- March 30, 2018
financing immune Market Views
Merck KGaA adopts Medisafe medication adherence tool for patients with chronic conditions

Patients can access their record through a code for their iPhone. The idea is to help patients better understand their medical history, improve the quality of interactions with their physicians and family members, and make more informed decisions about their care.
- Source: MedCityNews
- 584
- March 30, 2018
Company Insights digital health EHR
Alnylam Presents New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the 16th International Symposium on Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced that the Company presented new results from the APOLLO Phase 3 study of patisiran, an investigational, RNAi therapeutic for the treatment of hereditary ATTR (hATTR) amyloidosis at the 16th International Symposium on Amyloidosis (ISA), being held March 26-29, 2018 in Kumamoto, Japan. In addition, the Company presented new data from the Phase 1 study of ALN-TTRsc02, an investigational, subcutaneously administered RNAi therapeutic in development for the treatment of ATTR amyloidosis.
- Source: biospace
- 594
- March 30, 2018
ATTR amyloidosis Clinical Trials hereditary ATTR
Bigfoot brings in $55M Series B to propel integrated diabetes platform

This week, Bigfoot Biomedical announced a $55 million Series B to advance their push to integrate glucose monitoring, insulin delivery and smart software. The financing will support a pivotal trial and other efforts to gain premarket approval(PMA) from the FDA.
- Source: MedCityNews
- 828
- March 30, 2018
Company Insights diabetes FDA funding
FDA clears Medtronic’s smartphone-connected CGM for MDI users

Medtronic has finally received FDA clearance for Guardian Connect, its smartphone-connected standalone CGM for patients who use multiple daily injections (MDI) for their insulin. Medtronic's closed-loop system for pump users was cleared in 2016.
- Source: mobihealthnews
- 823
- March 30, 2018
FDA Guardian Connect insulin Medtronic New Approvals

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.